Wave Life Sciences Ltd. (1U5) Starts Phase 2a Obesity Combo Trial
Wave Life Sciences began a placebo-controlled Phase 2a trial of WVE-007 with weekly tirzepatide in adults with obesity and type 2 diabetes, testing 240 mg and 400 mg doses. A maintenance trial post-incretin cessation is expected to start in 2H 2026.Material DetailsContext by AI AnalystThis is an R…